All In Biotech

Drug Trial Radar · NCT05852431

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 369 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

369

Actual

Start

Jun 15, 2023

Primary completion

Jul 7, 2025

Study completion Apr 9, 2026

Sponsor

Lead sponsor
89bio, Inc.Industry
Sponsor type
Industry
First posted
May 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • PegozaferminDrug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in fasting TGTime frame: 26 weeks

Locations

177 sites in 20 countries. Site status is shown where the registry gives one.

  • 89bio Clinical Study Site

    Chandler, Arizona

  • 89bio Clinical Study Site

    Peoria, Arizona

  • 89Bio Clinical Study Site

    Tucson, Arizona

  • 89bio Clinical Study Site

    Conway, Arkansas

  • 89bio Clinical Study Site

    Jonesboro, Arkansas

  • 89bio Clinical Study Site

    Little Rock, Arkansas

  • 89bio Clinical Trial Site

    Huntington Park, California

  • 89Bio Clinical Study Site

    Long Beach, California

  • 89bio Clinical Study Site

    Los Angeles, California

  • 89bio Clinical Trial Site

    Northridge, California

  • 89bio Clinical Trial Site

    Panorama City, California

  • 89bio Clinical Study Site

    Santa Ana, California

  • 89bio Clinical Trial Site

    Santa Ana, California

  • 89bio Clinical Study Site

    Thousand Oaks, California

  • 89Bio Clinical Study Site

    Tustin, California

  • 89bio Clinical Study Site

    Wheat Ridge, Colorado

  • 89bio Clinical Trial Site

    Wheat Ridge, Colorado

  • 89bio Clinical Study Site

    Bridgeport, Connecticut

  • 89Bio Clinical Study Site

    Clearwater, Florida

  • 89bio Clinical Study Site

    Clearwater, Florida

  • 89bio Clinical Study Site

    Hialeah Gardens, Florida

  • 89Bio Clinical Study Site

    Homestead, Florida

  • 89Bio Clinical Study Site

    Miami Lakes, Florida

  • 89bio Clinical Study Site

    Miramar, Florida

  • 89Bio Clinical Study Site

    Orlando, Florida

  • 89bio Clinical Study Site

    Panama City, Florida

  • 89bio Clinical Trial Site

    Port Orange, Florida

  • 89Bio Clinical Study Site

    Tampa, Florida

  • 89bio Clinical Study Site

    Atlanta, Georgia

  • 89Bio Clinical Study Site

    Columbus, Georgia

  • 89Bio Clinical Study Site

    Lawrenceville, Georgia

  • 89Bio Clinical Study Site

    Chicago, Illinois

  • 89bio Clinical Study Site

    West Des Moines, Iowa

  • 89Bio Clinical Study Site

    Wichita, Kansas

  • 89Bio Clinical Study Site

    Marrero, Louisiana

  • 89bio Clinical Trial Site

    Shreveport, Louisiana

  • 89Bio Clinical Study Site

    Oxon Hill, Maryland

  • 89bio Clinical Study Site

    Flint, Michigan

  • 89bio Clinical Trial Site

    Kansas City, Missouri

  • 89bio Clinical Study Site

    St Louis, Missouri

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.